Cart
sales@molnova.com
NG-Nitroarginine methyl ester
CAS No. 50903-99-6
NG-Nitroarginine methyl ester( L-NAME | ω-Nitroarginine methyl )
Catalog No. M27824 CAS No. 50903-99-6
NG-Nitroarginine methyl ester is a non-selective nitric oxide synthase inhibitor. It has been utilized experimentally to induce hypertension.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 302 | Get Quote |
|
| 10MG | 447 | Get Quote |
|
| 25MG | 714 | Get Quote |
|
| 50MG | 1017 | Get Quote |
|
| 100MG | 1368 | Get Quote |
|
| 500MG | 2673 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNG-Nitroarginine methyl ester
-
NoteResearch use only, not for human use.
-
Brief DescriptionNG-Nitroarginine methyl ester is a non-selective nitric oxide synthase inhibitor. It has been utilized experimentally to induce hypertension.
-
DescriptionNG-Nitroarginine methyl ester is a non-selective nitric oxide synthase inhibitor. It has been utilized experimentally to induce hypertension.
-
In Vitro——
-
In Vivo——
-
SynonymsL-NAME | ω-Nitroarginine methyl
-
PathwayImmunology/Inflammation
-
TargetNOS
-
RecptorTLR7
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number50903-99-6
-
Formula Weight233.228
-
Molecular FormulaC7H15N5O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
L-NIL
L-NIL is a selective nitric oxide synthase (iNOS) inhibitor that reverses burn-induced activation of glycogen synthase kinase-3β in rat skeletal muscle and may slow the progression of squamous cell carcinoma lung.
-
Rutaevin
Rutaevin shows the inhibitory activity on nitric oxide (NO) production in lipopolysaccharide-activated RAW264.7 macrophages, it may be as a valuable anti-inflammatory agent.
-
TP508
TP508 is a 23 amino acid synthetic peptide representing residues 508-530 of human prothrombin which is identified as a potential receptor-binding domain based on competition for high-affinity thrombin binding to fibroblasts.TP508 (Chrysalin) is an investigational peptide drug that was developed for use in stimulating repair of dermal and musculoskeletal tissues.
